Utility of Respiratory Biomarker Guidance in Exacerbations (URGE)
Utility of Respiratory Biomarker Guidance in Exacerbations (URGE): a Pragmatic, Randomized, Open-Label, Single-Center Superiority Trial of Dual Point-of-Care Testing to Reduce Antibiotic Use in Adults Presenting to the Emergency Department With Asthma or COPD Exacerbations
People with asthma or chronic obstructive pulmonary disease (COPD) often come to the emergency department because their breathing suddenly gets worse. These flare-ups are called exacerbations. Many of these episodes are caused by viruses or inflammation, not bacteria. However, clinicians still frequently prescribe antibiotics, even when they are unlikely to help. Unnecessary antibiotic use can cause side effects, increase healthcare costs, and contribute to antibiotic resistance, which is a growing public health problem.
The URGE study aims to find a better way to decide when antibiotics are truly needed during asthma or COPD attacks in the emergency department. The study will test whether using two rapid bedside tests can safely reduce unnecessary antibiotic prescriptions.
The first test is a rapid molecular test that looks for common respiratory viruses and certain bacteria using a nasopharyngeal swab. Results are available within about 15 to 20 minutes. The second test measures C-reactive protein (CRP) from a small blood sample. CRP is an inflammation marker that tends to be higher when a bacterial infection is present. Together, these tests give doctors quick information about whether an infection is likely viral, bacterial, or non-infectious.
URGE will recruit 200 adults who come to the emergency department with an asthma or COPD exacerbation to take part in the study. After providing consent, participants will be randomly assigned to one of two groups. In both groups, participants will complete both rapid tests. In one group, the test results will be shared with the treating doctor right away and can be used to help guide treatment decisions. In the other group, the doctor will not see the test results, and care will follow usual practice. Doctors will always be free to make their own clinical decisions, regardless of test results.
The main outcome the study will measure is whether or not patients are prescribed antibiotics when they leave the emergency department or are admitted to hospital. The study will also examine how long patients take antibiotics, hospital admissions, return visits to healthcare services, and patient satisfaction. Participants will be followed up by phone and through medical record review at 7 days and 30 days after their emergency visit to ensure they recover safely.
The URGE trial will study tests that are already approved and commonly used in healthcare. The goal is not to deny needed treatment, but to better match treatment to the cause of the flare-up. If successful, this approach could reduce unnecessary antibiotic use, improve patient care, and support safer, more sustainable treatment of asthma and COPD exacerbations in emergency departments.
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
Acute exacerbations of asthma and COPD are frequent causes of emergency department (ED) visits worldwide, with a substantial proportion of patients receiving antibiotics - often inappropriately - despite a likely viral or non-infectious etiology [1,2]. This practice contributes to antimicrobial resistance, patient harm, and unnecessary healthcare costs [3-8]. While guidelines emphasize the judicious use of antibiotics, real-time decision-making in the ED is often constrained by diagnostic uncertainty. Current approaches recommended by guidelines (GINA, GOLD, INESSS) rely heavily on symptom severity and do not systematically integrate host inflammatory or pathogen-specific data [9-12].
Leveraging evidence from previous randomized controlled trial post hoc analyses, the URGE trial is a pragmatic, randomized, open-label study designed to evaluate whether dual point-of-care testing (POCT) - combining rapid molecular microbial PCR (Polymerase Chain Reaction) testing and C-reactive protein (CRP) - can reduce antibiotic use in adults presenting to the ED with an asthma or COPD attack. This dual biomarker strategy aims to enhance diagnostic precision by integrating pathogen detection with host inflammatory responses, thereby guiding real-time, targeted decisions.
A total of 200 patients will be targeted, recruiting until at least 124 analysable patients have completed the trial. All participants will undergo microbial PCR and CRP testing after randomisation and will be managed in accordance with current clinical practice guidelines. In the intervention group, PCR and CRP results will be available to treating clinicians at the time of evaluation and used to inform management decisions. In the control group, test results will not be available to clinicians. The primary outcome is the proportion of patients prescribed antibiotics at ED discharge. Secondary outcomes include antibiotic duration, hospital admissions, revisit rates, and patient acceptability.
URGE is grounded in a growing body of evidence suggesting that either molecular microbial PCR alone or CRP can reduce antibiotic prescribing in acute respiratory illness. Molecular microbial POCT enables rapid identification of respiratory pathogens, whereas CRP reflects the host's systemic inflammatory response - particularly in response to bacterial infections- thereby facilitating early exclusion of a bacterial etiology. However, to date, no randomized trials have assessed the combined impact of these two complementary biomarkers in a real-world emergency care setting. URGE is the first study to evaluate whether integrating both markers into a unified triage strategy can synergistically improve antibiotic stewardship in patients with asthma and COPD attacks.
If successful, the URGE trial will pave the way for a biomarker-guided, proactive approach to antibiotic stewardship in acute airway disease, shifting ED management from a "treat all" paradigm to one that integrates real-time microbial identification by PCR and CRP-based inflammatory profiling. This study will inform the design of larger multicenter implementation trials and help transform care for respiratory infections in the ED.
This protocol is reported in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2025 reporting guideline [13].
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Ilmoittautuminen
Vaihe
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Quebec
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- CIUSSS de l'Estrie-CHUS, Hôpital Fleurimont
-
Päätutkija:
- Simon Couillard, MD
-
Ottaa yhteyttä:
- Sähköposti: s.couillard@usherbrooke.ca
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
-
Adults aged ≥18 years at the time of signing the informed consent.
-
Presenting to the ED with a clinical diagnosis of asthma or COPD exacerbation, defined as an acute (<14 days) worsening of respiratory symptoms beyond baseline (e.g. increased dyspnea, cough, sputum, or wheezing) requiring urgent evaluation.
-
Established diagnosis of asthma or COPD for > 1 month*, based on:
-
For asthma: documented variability in airflow limitation (e.g., spirometric reversibility ≥12% and ≥200 mL in FEV1, or positive bronchial provocation testing), consistent with GINA 2025.
-
For COPD: post-bronchodilator FEV1/FVC <0.70 or below the LLN with ≥10 pack-years smoking history and compatible symptoms, consistent with GOLD 2026.
*Patients with physician-diagnosed disease, without objective testing, may undergo confirmatory testing < 3 months after URGE trial participation to confirm eligibility.
-
Antibiotics were not ordered at the time of randomisation.
-
Able to provide signed, informed consent within the ED care window.
-
Willingness to undergo molecular microbial PCR and CRP at the point-of-care before antibiotic decision.
Exclusion Criteria:
Medical conditions
- Clinical concern for sepsis at the time of enrolment: Altered mental status or Systolic blood pressure ≤ 100 mm Hg, unless consistent with the patient's usual baseline and without other signs of hypoperfusion.
- Current systemic antibiotic for acute respiratory illness at time of evaluation.
- Chronic systemic corticosteroid use for any indication. The first systemic corticosteroid dose given before or in the ED for the index exacerbation is permitted and does not constitute exclusion.
- Known significant chronic respiratory disease other than asthma or COPD, including interstitial lung disease, pulmonary hypertension, cystic fibrosis, clinically significant bronchiectasis.
- Acute use of non-invasive ventilation (NIV).
- History of active malignancy within the past 6 months, excluding: non-melanoma skin cancer or localized cervical dysplasia / in situ cancer.
- Significant immunosuppression or ongoing systemic immunosuppressive therapy (e.g., methotrexate or other immunosuppressive disease-modifying antirheumatic drugs (DMARDs), transplant recipients, chemotherapy).
- End-stage organ disease (e.g., decompensated heart failure, end-stage renal or liver disease).
- Severe cognitive impairment or inability to provide informed consent.
- Pregnancy or breastfeeding.
- Previous participation in the URGE study (participants may be enrolled only once).
- Known (test-positive) viral infection within the past 7 days.
- Diagnosis of pneumonia with chest X-ray made at the index visit at the clinician's discretion.
- Concurrent acute coronary syndrome (either primary or secondary).
- Decompensated heart failure.
- New-onset arrhythmia.
- Vaccination against influenza with FluMist® within 14 days prior.
Logistical or Operational Exclusions
- Patient is unable or unwilling to undergo both POCTs.
- Expected discharge to long-term care facility or hospice.
- Patient self-discharges before meeting emergency care physician
Other exclusions
-Individuals are accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalised.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Terveyspalvelututkimus
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: POCT results disclosed
Dual POCT results (multiplex PCR + CRP) are disclosed in real time to the treating physician, together with a predefined advisory PCR+CRP antibiotic algorithm; results are communicated to the patient. Clinicians may override the algorithm. |
Rapid, point-of-care (POC) tests at the ED visit
Muut nimet:
Rapid, point-of-care (POC) tests at the ED visit.
Muut nimet:
Multiplex PCR and CRP results are disclosed in real time to the treating physician (written note in the EMR triage section), together with a predefined advisory antibiotic algorithm. Results are communicated to the patient by the treating physician. Clinicians may override the algorithm at any time. |
|
Muut: POCT results non disclosed
Participants undergo the same dual POCT (PCR + CRP) under identical conditions, but results are not disclosed to the treating physician or the participant during the index visit. Usual care per clinician judgment. |
Rapid, point-of-care (POC) tests at the ED visit
Muut nimet:
Rapid, point-of-care (POC) tests at the ED visit.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Proportion of participants prescribed antibiotics at ED discharge
Aikaikkuna: At ED discharge or hospital admission (assessed up to 5 days)
|
Prescription of any antibiotic at ED discharge |
At ED discharge or hospital admission (assessed up to 5 days)
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Proportion of patients receiving only a single dose of antibiotics
Aikaikkuna: During ED stay (assessed up to 5 days)
|
Single-dose antibiotic administration |
During ED stay (assessed up to 5 days)
|
|
Proportion of patients receiving intravenous (IV) antibiotics
Aikaikkuna: During ED stay (assessed up to 5 days)
|
Intravenous antibiotic administration during ED stay |
During ED stay (assessed up to 5 days)
|
|
Total duration of oral antibiotic use
Aikaikkuna: From initiation to discontinuation (assessed up to 30 days)
|
Number of days of oral antibiotic therapy |
From initiation to discontinuation (assessed up to 30 days)
|
|
Total duration of IV antibiotic use
Aikaikkuna: During ED stay and/or hospitalization (assessed up to 30 days)
|
Number of days of intravenous antibiotic therapy |
During ED stay and/or hospitalization (assessed up to 30 days)
|
|
Antibiotic prescription after ED discharge
Aikaikkuna: Day 7 and Day 30
|
New antibiotic prescriptions after discharge for patients who did not receive one at discharge, and the time until that prescription was issued. |
Day 7 and Day 30
|
|
ED length of stay
Aikaikkuna: From ED registration to ED discharge or admission order (assessed up to 5 days)
|
Hours from ED registration to discharge or admission order |
From ED registration to ED discharge or admission order (assessed up to 5 days)
|
|
Hospital admission rate
Aikaikkuna: During index ED visit (assessed up to 5 days)
|
Admission to hospital after ED evaluation |
During index ED visit (assessed up to 5 days)
|
|
Length of hospital stay
Aikaikkuna: From hospital admission to discharge (assessed up to 30 days)
|
Duration from hospital admission to discharge |
From hospital admission to discharge (assessed up to 30 days)
|
|
Corticosteroid prescribing at ED discharge
Aikaikkuna: At ED discharge (assessed up to 5 days)
|
Prescription of systemic corticosteroids |
At ED discharge (assessed up to 5 days)
|
|
Oseltamivir prescribing at ED discharge
Aikaikkuna: At ED discharge (assessed up to 5 days)
|
Oseltamivir prescription in PCR-confirmed influenza |
At ED discharge (assessed up to 5 days)
|
|
Time to oseltamivir initiation
Aikaikkuna: From randomization to first oseltamivir dose (assessed up to 30 days)
|
Time from randomization to first oseltamivir dose in PCR-confirmed influenza |
From randomization to first oseltamivir dose (assessed up to 30 days)
|
|
Duration of oseltamivir use
Aikaikkuna: Through Day 30 follow-up
|
Number of days of oseltamivir treatment in PCR-confirmed influenza |
Through Day 30 follow-up
|
|
Isolation precautions applied (mask) during ED stay
Aikaikkuna: During ED stay, from ED arrival to ED discharge (assessed up to 5 days)
|
Participants with documented initiation of respiratory isolation precautions (mask use) at any time during the ED stay. |
During ED stay, from ED arrival to ED discharge (assessed up to 5 days)
|
|
Adverse events (AEs)
Aikaikkuna: Index ED visit, Day 7, and Day 30 follow-up
|
Proportion of participants with ≥1 adverse event (AE) and ≥1 serious adverse event (SAE). Severity according to CTCAE v5.0 (mild, moderate, severe). |
Index ED visit, Day 7, and Day 30 follow-up
|
|
In-hospital mortality
Aikaikkuna: Index ED visit and index hospital admission, up to discharge (assessed up to 30 days)
|
Death occurring during the index ED visit or during the subsequent index hospitalization (if admitted). Reported as all-cause and asthma/COPD-related. |
Index ED visit and index hospital admission, up to discharge (assessed up to 30 days)
|
|
Unscheduled primary care consultation
Aikaikkuna: Day 7 and Day 30 follow-up.
|
Any unplanned primary care visits after the index ED encounter. Reported as all-cause and asthma/COPD-related. |
Day 7 and Day 30 follow-up.
|
|
Unscheduled ED visits
Aikaikkuna: Day 7 and Day 30 follow-up
|
Return visits to any ED after the index encounter. Reported as all-cause and asthma/COPD-related |
Day 7 and Day 30 follow-up
|
|
Unscheduled hospital admission
Aikaikkuna: Day 7 and Day 30 follow-up
|
Any unplanned hospital admission after the index encounter. Reported as all-cause and asthma/COPD-related |
Day 7 and Day 30 follow-up
|
|
Mortality (all-cause and asthma/COPD-related)
Aikaikkuna: Day 7 and Day 30 follow-up
|
Death after the index ED visit, reported as all-cause and asthma/COPD-related |
Day 7 and Day 30 follow-up
|
Muut tulostoimenpiteet
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Time to obtain POCT PCR results
Aikaikkuna: Index ED visit (assessed up to 5 days)
|
Time from documented sample collection to PCR result availability on the POCT platform (device timestamp and/or documented availability for disclosure) |
Index ED visit (assessed up to 5 days)
|
|
Time to obtain POCT CRP results
Aikaikkuna: Index ED visit (assessed up to 5 days)
|
Time from documented sample collection to CRP result availability on the platform (device timestamp and/or documented availability for disclosure) |
Index ED visit (assessed up to 5 days)
|
|
Prevalence and distribution of respiratory viruses and bacteria detected
Aikaikkuna: Index ED visit (assessed up to 5 days)
|
Pathogen type detected by PCR |
Index ED visit (assessed up to 5 days)
|
|
Prevalence of influenza virus detected
Aikaikkuna: Index ED visit (assessed up to 5 days)
|
PCR-confirmed influenza detection |
Index ED visit (assessed up to 5 days)
|
|
Antibiotic decision-POCT concordance
Aikaikkuna: At ED discharge (assessed up to 5 days)
|
Algorithm-recommended antibiotic decision (discourage / consider / recommend) derived from the predefined CRP+PCR algorithm; and observed antibiotic prescribing status at ED discharge (yes/no), cross-classified with POCT profile (CRP strata and PCR result categories). |
At ED discharge (assessed up to 5 days)
|
|
Antibiotic prescribing based on CRP strata
Aikaikkuna: At ED discharge (assessed up to 5 days)
|
CRP level category (<20, 20-40, >40 mg/L) |
At ED discharge (assessed up to 5 days)
|
|
Time to antibiotic initiation
Aikaikkuna: From randomization to first antibiotic dose (assessed up to 30 days)
|
Time from randomization to first antibiotic administration (IV or oral) |
From randomization to first antibiotic dose (assessed up to 30 days)
|
|
Atypical pathogen-targeted antibiotic (e.g. macrolide) use among participants with positive PCR for atypical bacteria.
Aikaikkuna: During ED stay (assessed up to 5 days)
|
Initiation of an atypical pathogen-targeted antibiotic (e.g. macrolide) among participants with PCR-detected atypical bacteria |
During ED stay (assessed up to 5 days)
|
|
Patient satisfaction and acceptability of POCT strategy
Aikaikkuna: At ED visit (assessed up to 5 days)
|
Patient-reported satisfaction |
At ED visit (assessed up to 5 days)
|
|
POCT-Laboratory PCR concordance
Aikaikkuna: At ED visit (assessed up to 5 days)
|
Concordance between POCT PCR results and routine laboratory results when both are performed during the index ED visit |
At ED visit (assessed up to 5 days)
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Yhteistyökumppanit
Yhteistyökumppanit
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Opiskelun aloitus
Ensisijainen valmistuminen (Arvioitu)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Patologiset prosessit
- Krooninen sairaus
- Sairauden ominaisuudet
- Immuunijärjestelmän sairaudet
- Hengityselinten sairaudet
- Keuhkosairaudet
- Keuhkoputken sairaudet
- Keuhkosairaudet, obstruktiiviset
- Hengitysteiden yliherkkyys
- Yliherkkyys, välitön
- Yliherkkyys
- Patologiset tilat, merkit ja oireet
- Keuhkosairaus, krooninen obstruktiivinen
- Astma
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- 0002
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
De-identified individual participant data (IPD) will be shared for all participants who consent to third-party data sharing. This includes the data underlying the published results: baseline demographic and clinical characteristics, eligibility variables, randomization arm, point-of-care test results (multiplex PCR and CRP), intervention adherence (POCT disclosure and algorithm concordance), primary and secondary outcomes (antibiotic prescribing, healthcare utilization, mortality), and adverse events. A complete data dictionary will be provided with the dataset. Data will be coded with study IDs, and all direct identifiers will be removed to prevent re-identification.
IPD-jaon aikakehys
Beginning after publication of the primary outcome results and available for at least 15 years thereafter.
IPD-jaon käyttöoikeuskriteerit
Researchers must submit a research proposal to the study investigators. Access requires approval by the investigators, a signed data-sharing agreement, and ethics approval where applicable. Data will be provided through a controlled-access repository at Université de Sherbrooke.
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- MAHLA
- ICF
- ANALYTIC_CODE
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .